Company news
Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) news
Eledon Pharmaceuticals, Inc. news releases on 6ix. Latest, Mar 25, 2024: Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial…
Press releases — page 2
Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ Rejection
March 24, 2024
Eledon Pharmaceuticals Announces Use of Tegoprubart in First-ever Transplant of Genetically Modified Kidney from a Pig to a Human
March 20, 2024
Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 12, 2024
Eledon Pharmaceuticals Reports Third Quarter 2023 Operating and Financial Results
November 8, 2023
Eledon Reports Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation
November 1, 2023
Eledon Pharmaceuticals Strengthens Leadership Team with Appointment of Eliezer Katz, M.D., FACS as Chief Medical Officer
October 22, 2023
Eledon Pharmaceuticals to Present Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Society of Nephrology Kidney Week 2023 Annual Meeting
October 12, 2023
Eledon Pharmaceuticals Appoints Kidney Transplant Specialist Dr. Allan Douglas Kirk to Board of Directors
October 1, 2023
Eledon Pharmaceuticals Announces Use of Tegoprubart anti-CD40L Antibody in Second-ever Transplant of Genetically Modified Heart from a Pig to a Human
September 24, 2023
Eledon Pharmaceuticals Appoints Industry Veteran James Robinson to its Board of Directors
September 10, 2023
Eledon Pharmaceuticals Announces Publication of Data Showing Treatment with Tegoprubart Promotes Kidney and Islet Allograft Survival and Function in Nonhuman Primates
September 5, 2023
Eledon Pharmaceuticals Announces First Participant Dosed in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Rejection in Kidney Transplantation
September 4, 2023
Eledon Pharmaceuticals Announces Dosing of 10th Patient in Ongoing Phase 1b Trial Evaluating Tegoprubart in Patients Undergoing Kidney Transplantation
August 15, 2023
Eledon Pharmaceuticals Reports Second Quarter 2023 Operating and Financial Results
August 9, 2023
Eledon Pharmaceuticals Reports First Quarter 2023 Operating and Financial Results
May 10, 2023
Eledon Pharmaceuticals to Report First Quarter 2023 Financial Results on Thursday, May 11, 2023
May 3, 2023
Eledon Pharmaceuticals Announces up to $185 Million Financing to Advance Tegoprubart Kidney Transplantation Clinical Trials
April 30, 2023
Eledon Reports Data from Ongoing Phase 1b Trial Evaluating Tegoprubart in Patients Undergoing Kidney Transplantation at World Congress of Nephrology
March 30, 2023
Eledon Pharmaceuticals Reports Fourth Quarter and Full-Year 2022 Operating and Financial Results
March 29, 2023
Eledon to Present Data from Ongoing Phase 1b Trial Evaluating Tegoprubart in Kidney Transplantation at the World Congress of Nephrology 2023
March 22, 2023
Eledon Pharmaceuticals Provides Business and Pipeline Updates
January 8, 2023
Eledon Pharmaceuticals Reports Third Quarter 2022 Operating and Financial Results
November 13, 2022
Eledon Pharmaceuticals Announces Upcoming Presentations at ASN’s Kidney Week 2022 and NEALS
October 23, 2022
Eledon Pharmaceuticals Receives FDA Clearance of IND Application to Evaluate Tegoprubart in IgA Nephropathy
September 5, 2022
Eledon Pharmaceuticals Reports Second Quarter 2022 Operating and Financial Results
August 10, 2022
Eledon Pharmaceuticals Receives FDA Clearance of IND Application to Evaluate Tegoprubart for the Prevention of Rejection in Kidney Transplant Recipients
July 31, 2022
Eledon Pharmaceuticals Announces the First Patient Dosed in Phase 1b Trial Evaluating Tegoprubart in Kidney Transplantation
July 17, 2022
Eledon Pharmaceuticals Announces Orphan Drug Designation Granted to Tegoprubart for the Prevention of Allograft Rejection in Pancreatic Islet Cell Transplantation
June 8, 2022
Eledon Announces Positive Topline Results from Phase 2a Trial of Tegoprubart Demonstrating Safety, Target Engagement, and Biomarker Response in Patients Living with Amyotrophic Lateral Sclerosis
May 30, 2022
Eledon Pharmaceuticals Reports First Quarter 2022 Operating and Financial Results
May 11, 2022
Eledon Pharmaceuticals Announces First Patient Dosed in Phase 2a Trial Evaluating Tegoprubart in IgA Nephropathy
May 8, 2022
Eledon to Host Virtual R&D Day on Thursday, April 28, 2022
April 13, 2022
Eledon Pharmaceuticals Reports Fourth Quarter and Full-Year 2021 Operating and Financial Results
March 23, 2022
Eledon Pharmaceuticals Provides Corporate Update and 2022 Outlook
February 13, 2022
Eledon Pharmaceuticals Reports Third Quarter 2021 Operating and Financial Results
November 10, 2021
Eledon Pharmaceuticals Announces Participation in November Conferences
November 3, 2021
Eledon Pharmaceuticals to Release Third Quarter Financial Results on Thursday, November 11, 2021
October 31, 2021
Eledon Pharmaceuticals Announces Presentation on AT-1501 at the Virtual 2021 Northeast Amyotrophic Lateral Sclerosis Consortium
October 6, 2021
Eledon Pharmaceuticals Announces Upcoming Presentation on AT-1501 at the Virtual 2021 International Pancreas and Islet Transplantation Association Congress
October 4, 2021
Eledon Pharmaceuticals Reports Second Quarter 2021 Operating and Financial Results
August 11, 2021
Eledon Pharmaceuticals Receives Health Canada Approval to Commence Human Trials to Evaluate AT-1501 in Kidney Transplantation
July 25, 2021
Eledon Pharmaceuticals Appoints Jan Hillson, M.D., to its Board of Directors
July 1, 2021
Eledon Pharmaceuticals Reports First Quarter 2021 Operating and Financial Results
May 12, 2021
Eledon Pharmaceuticals Announces Upcoming Presentations on AT-1501 at the Virtual 2021 American Transplant Congress
May 4, 2021
Eledon Pharmaceuticals to Release First Quarter Financial Results on Thursday, May 13, 2021
May 3, 2021
Eledon Pharmaceuticals Announces Update on Development Strategy for AT-1501 in Renal Transplantation
April 25, 2021
Eledon Pharmaceuticals Continues to Bolster Leadership Team with Addition of Two More Key Executives
April 18, 2021
Eledon Pharmaceuticals to Release Fourth Quarter and Full-Year Financial Results on Tuesday, March 30
March 22, 2021
Eledon Pharmaceuticals Strengthens Leadership Team with Chief Medical Officer and Chief Financial Officer Hires
March 14, 2021